Redcliffe Labs vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Redcliffe Labs logo

Redcliffe Labs

ChallengerHealthcare

Diagnostic Testing & Precision Medicine

Redcliffe Labs is an India-based diagnostics and precision medicine company offering at-home sample collection, genetic testing, and reproductive health diagnostics; raised $21.5M in 2023;

AI VisibilityBeta
Overall Score
C53
Category Rank
#221 of 596
AI Consensus
93%
Trend
stable
Per Platform
ChatGPT
47
Perplexity
50
Gemini
49

About

Redcliffe Labs is an Indian diagnostics and precision medicine company founded in 2019 by Dhruv Gupta and headquartered in Gurugram, India. The company operates a technology-enabled diagnostic testing platform offering home sample collection, lab processing, and digital report delivery across more than 2,000 cities in India. Beyond standard blood panels and routine diagnostics, Redcliffe Labs specializes in advanced and specialized testing including reproductive health (fertility, pregnancy, prenatal screening), rare disease detection, cancer gene diagnostics (oncology genetic panels), and whole genome sequencing — areas that most large-scale Indian diagnostics chains do not prioritize.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#221
Category Rank
#1
93
AI Consensus
80
stable
Trend
stable
47
ChatGPT
94
50
Perplexity
89
49
Gemini
94
48
Claude
92
49
Grok
98

Key Details

Category
Diagnostic Testing & Precision Medicine
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.